Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(13%)
Results Posted
25%(1 trials)

Phase Distribution

Ph early_phase_1
1
13%
Ph phase_1
4
50%
Ph not_applicable
3
38%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Early Phase 1First-in-human
1(12.5%)
Phase 1Safety & dosage
4(50.0%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(4)
Terminated(3)

Detailed Status

Completed4
Withdrawn3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Early Phase 11 (12.5%)
Phase 14 (50.0%)
N/A3 (37.5%)

Trials by Status

completed450%
active_not_recruiting113%
withdrawn338%

Recent Activity

1 active trials
Showing 5 of 8
withdrawnphase_1

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

NCT07387354
active_not_recruitingnot_applicable

Cardiac Outcomes With Near-Complete Estrogen Deprivation

NCT05309655
withdrawnearly_phase_1

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
withdrawnnot_applicable

A Study to Assess the Use of The Sentinel Device During Atrial Fibrillation Ablation

NCT04683692
completedphase_1

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07387354Phase 1

Pacritinib With Aza for Upfront Myelodysplastic Syndrome

Withdrawn
NCT05309655Not Applicable

Cardiac Outcomes With Near-Complete Estrogen Deprivation

Active Not Recruiting
NCT05119712Early Phase 1

Terbinafine Treatment of Axial Spondyloarthropathy

Withdrawn
NCT04683692Not Applicable

A Study to Assess the Use of The Sentinel Device During Atrial Fibrillation Ablation

Withdrawn
NCT03793439Phase 1

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

Completed
NCT02901028Not Applicable

Innovative Concussion Prevention Device

Completed
NCT00968409Phase 1

Assessment of Progesterone Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using Fluoro Furanyl Norprogesterone (FFNP)

Completed
NCT00968656Phase 1

Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1

Completed

All 8 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
8